This study explored a new model of Prostate Imaging Reporting and Data System(PIRADS)and adjusted prostate-specific antigen density of peripheral zone(aPSADPZ)for predicting the occurrence of prostate cancer(PCa)and c...This study explored a new model of Prostate Imaging Reporting and Data System(PIRADS)and adjusted prostate-specific antigen density of peripheral zone(aPSADPZ)for predicting the occurrence of prostate cancer(PCa)and clinically significant prostate cancer(csPCa).The demographic and clinical characteristics of 853 patients were recorded.Prostate-specific antigen(PSA),PSA density(PSAD),PSAD of peripheral zone(PSADPZ),aPSADPZ,and peripheral zone volume ratio(PZ-ratio)were calculated and subjected to receiver operating characteristic(ROC)curve analysis.The calibration and discrimination abilities of new nomograms were verified with the calibration curve and area under the ROC curve(AUC).The clinical benefits of these models were evaluated by decision curve analysis and clinical impact curves.The AUCs of PSA,PSAD,PSADPZ,aPSADPZ,and PZ-ratio were 0.669,0.762,0.659,0.812,and 0.748 for PCa diagnosis,while 0.713,0.788,0.694,0.828,and 0.735 for csPCa diagnosis,respectively.All nomograms displayed higher net benefit and better overall calibration than the scenarios for predicting the occurrence of PCa or csPCa.The new model significantly improved the diagnostic accuracy of PCa(0.945 vs 0.830,P<0.01)and csPCa(0.937 vs 0.845,P<0.01)compared with the base model.In addition,the number of patients with PCa and csPCa predicted by the new model was in good agreement with the actual number of patients with PCa and csPCa in high-risk threshold.This study demonstrates that aPSADPZ has a higher predictive accuracy for PCa diagnosis than the conventional indicators.Combining aPSADPZ with PIRADS can improve PCa diagnosis and avoid unnecessary biopsies.展开更多
目的:探讨前列腺特异抗原(prostate specific antigen,PSA)、前列腺特异性抗原密度(prostate specific antigen density,PSAD)及移行带前列腺特异性抗原密度(pros-tate specific antigen density of transition zone,PSAD-TZ)用于前列...目的:探讨前列腺特异抗原(prostate specific antigen,PSA)、前列腺特异性抗原密度(prostate specific antigen density,PSAD)及移行带前列腺特异性抗原密度(pros-tate specific antigen density of transition zone,PSAD-TZ)用于前列腺癌筛选时前列腺体积和患者年龄因素对其的影响。方法:回顾性分析因PSA升高和(或)直肠指检异常疑诊前列腺癌而进行直肠前列腺穿刺活组织检查(活检)的295例男性患者的临床资料,根据活检结果分为BPH组(193例)和前列腺癌组(102例),比较2组中不同前列腺体积以及不同年龄段的PSA、PSAD及PSAD-TZ水平。结果:当前列腺体积小于或等于50mL时,BPH组的PSA、PS-AD及PSAD-TZ值与前列腺癌组比较差异均有统计学意义(P<0.01);当前列腺体积大于50mL时,2组的PSA值比较差异无统计学意义(P>0.05),但PSAD及PSAD-TZ值比较差异有统计学意义(均为P<0.01)。2组的PSA值随着年龄的增加而升高(均为P<0.01)。在50～59岁者和60～69岁者中,2组的PSAD及PSAD-TZ值比较差异均有统计学意义(P<0.05～0.01);在70～79岁者中,2组的PSAD及PSA-TZ值比较差异无统计学意义。结论:当前列腺体积小于或等于50mL时,检测PSA、PSAD及PSAD-TZ值对前列腺癌的筛选有重要意义,而前列腺体积大于50mL时,需结合PSAD、PSAD-TZ值以及患者的年龄作综合分析。展开更多
基金supported by two grants from the Key Research and Development Program of jiangsu Province (No.BE2020654 and No.BE2020655)a grant from the General Program of Jiangsu Health Commission (No.H2019040)a grant from National Key R&D Program of China (No.2017YFC0114303).
文摘This study explored a new model of Prostate Imaging Reporting and Data System(PIRADS)and adjusted prostate-specific antigen density of peripheral zone(aPSADPZ)for predicting the occurrence of prostate cancer(PCa)and clinically significant prostate cancer(csPCa).The demographic and clinical characteristics of 853 patients were recorded.Prostate-specific antigen(PSA),PSA density(PSAD),PSAD of peripheral zone(PSADPZ),aPSADPZ,and peripheral zone volume ratio(PZ-ratio)were calculated and subjected to receiver operating characteristic(ROC)curve analysis.The calibration and discrimination abilities of new nomograms were verified with the calibration curve and area under the ROC curve(AUC).The clinical benefits of these models were evaluated by decision curve analysis and clinical impact curves.The AUCs of PSA,PSAD,PSADPZ,aPSADPZ,and PZ-ratio were 0.669,0.762,0.659,0.812,and 0.748 for PCa diagnosis,while 0.713,0.788,0.694,0.828,and 0.735 for csPCa diagnosis,respectively.All nomograms displayed higher net benefit and better overall calibration than the scenarios for predicting the occurrence of PCa or csPCa.The new model significantly improved the diagnostic accuracy of PCa(0.945 vs 0.830,P<0.01)and csPCa(0.937 vs 0.845,P<0.01)compared with the base model.In addition,the number of patients with PCa and csPCa predicted by the new model was in good agreement with the actual number of patients with PCa and csPCa in high-risk threshold.This study demonstrates that aPSADPZ has a higher predictive accuracy for PCa diagnosis than the conventional indicators.Combining aPSADPZ with PIRADS can improve PCa diagnosis and avoid unnecessary biopsies.
文摘目的:探讨前列腺特异抗原(prostate specific antigen,PSA)、前列腺特异性抗原密度(prostate specific antigen density,PSAD)及移行带前列腺特异性抗原密度(pros-tate specific antigen density of transition zone,PSAD-TZ)用于前列腺癌筛选时前列腺体积和患者年龄因素对其的影响。方法:回顾性分析因PSA升高和(或)直肠指检异常疑诊前列腺癌而进行直肠前列腺穿刺活组织检查(活检)的295例男性患者的临床资料,根据活检结果分为BPH组(193例)和前列腺癌组(102例),比较2组中不同前列腺体积以及不同年龄段的PSA、PSAD及PSAD-TZ水平。结果:当前列腺体积小于或等于50mL时,BPH组的PSA、PS-AD及PSAD-TZ值与前列腺癌组比较差异均有统计学意义(P<0.01);当前列腺体积大于50mL时,2组的PSA值比较差异无统计学意义(P>0.05),但PSAD及PSAD-TZ值比较差异有统计学意义(均为P<0.01)。2组的PSA值随着年龄的增加而升高(均为P<0.01)。在50～59岁者和60～69岁者中,2组的PSAD及PSAD-TZ值比较差异均有统计学意义(P<0.05～0.01);在70～79岁者中,2组的PSAD及PSA-TZ值比较差异无统计学意义。结论:当前列腺体积小于或等于50mL时,检测PSA、PSAD及PSAD-TZ值对前列腺癌的筛选有重要意义,而前列腺体积大于50mL时,需结合PSAD、PSAD-TZ值以及患者的年龄作综合分析。
